ATE470150T1 - Methode zum schnellen identifizieren von kleinen organischen liganden - Google Patents

Methode zum schnellen identifizieren von kleinen organischen liganden

Info

Publication number
ATE470150T1
ATE470150T1 AT99931882T AT99931882T ATE470150T1 AT E470150 T1 ATE470150 T1 AT E470150T1 AT 99931882 T AT99931882 T AT 99931882T AT 99931882 T AT99931882 T AT 99931882T AT E470150 T1 ATE470150 T1 AT E470150T1
Authority
AT
Austria
Prior art keywords
small organic
biological target
ligands
binding
organic molecule
Prior art date
Application number
AT99931882T
Other languages
English (en)
Inventor
Jim Wells
Dan Erlanson
Andrew Braisted
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE470150T1 publication Critical patent/ATE470150T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99931882T 1998-06-26 1999-06-25 Methode zum schnellen identifizieren von kleinen organischen liganden ATE470150T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/105,372 US6335155B1 (en) 1998-06-26 1998-06-26 Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
PCT/US1999/014267 WO2000000823A1 (en) 1998-06-26 1999-06-25 Methods for rapidly identifying small organic ligands

Publications (1)

Publication Number Publication Date
ATE470150T1 true ATE470150T1 (de) 2010-06-15

Family

ID=22305449

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931882T ATE470150T1 (de) 1998-06-26 1999-06-25 Methode zum schnellen identifizieren von kleinen organischen liganden

Country Status (9)

Country Link
US (7) US6335155B1 (de)
EP (1) EP1090295B1 (de)
JP (1) JP2002519668A (de)
AT (1) ATE470150T1 (de)
AU (1) AU4829999A (de)
CA (1) CA2336183A1 (de)
DE (1) DE69942451D1 (de)
IL (2) IL140287A (de)
WO (1) WO2000000823A1 (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20050287596A9 (en) * 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6998233B2 (en) * 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6919178B2 (en) * 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
US7214487B2 (en) * 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US20030194745A1 (en) * 1998-06-26 2003-10-16 Mcdowell Robert S. Cysteine mutants and methods for detecting ligand binding to biological molecules
CA2403296A1 (en) 2000-04-10 2001-10-18 Benjamin F. Cravatt Proteomic analysis using activity-based probe libraries
US9708358B2 (en) 2000-10-06 2017-07-18 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding DNA and RNA
CA2425112C (en) 2000-10-06 2011-09-27 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding dna and rna
US20050084908A1 (en) * 2000-11-06 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Methods for detecting binding of low-molecular-weight compound and its binding partner molecule
DK1337853T3 (da) * 2000-11-21 2009-05-04 Sunesis Pharmaceuticals Inc Udvidet forankringstiltag til hurtig identifikation af ligander
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
AU2002247097A1 (en) 2001-02-05 2002-08-19 Activx Biosciences, Inc. Activity based probe analysis
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
DE10125258A1 (de) * 2001-05-23 2003-01-09 November Ag Molekulare Medizin Verfahren zur Bestimmung des Bindeverhaltens von an Ziel-Molekülen spezifisch bindenden Liganden
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
EP2000545B1 (de) 2001-06-20 2011-08-31 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Lungentumoren
IL159983A0 (en) * 2001-08-07 2004-06-20 Sunesis Pharmaceuticals Inc Disulfide and thiosulfonate ligands and libraries comprising these ligands
KR101008758B1 (ko) 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
GB0129012D0 (en) 2001-12-04 2002-01-23 Solexa Ltd Labelled nucleotides
KR100623128B1 (ko) 2002-01-02 2006-09-14 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
US20030186464A1 (en) * 2002-01-29 2003-10-02 Michelle Arkin Surface plasmon resonance methods
WO2003081210A2 (en) * 2002-03-21 2003-10-02 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
US20050084905A1 (en) * 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
AU2003226222A1 (en) * 2002-04-05 2003-10-27 Sunesis Pharmaceuticals, Inc. Methods of characterizing molecular interaction sites on proteins
AU2003224893A1 (en) * 2002-04-08 2003-10-27 Sunesis Pharmaceuticals, Inc. Methods for identifying allosteric sites
MXPA04010092A (es) 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
BRPI0215858B1 (pt) * 2002-07-24 2020-11-10 Keddem Bio-Science Ltd método para obter informações a respeito de uma área quimicamente ativa de uma molécula-alvo
JP2006509040A (ja) 2002-08-23 2006-03-16 ソレックサ リミテッド 修飾されたヌクレオチド
US11008359B2 (en) 2002-08-23 2021-05-18 Illumina Cambridge Limited Labelled nucleotides
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
US7019019B2 (en) * 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
AU2003290304A1 (en) 2002-12-23 2004-07-14 Astex Technology Limited Synthesis and screening of ligands using x-ray crystallography
ATE466953T1 (de) * 2003-01-17 2010-05-15 Advanced Proteome Therapeutics Verfahren zur identifizierung aktivierter polymer-komplexe zur sekundären stellen-spezifischen modifikation von protein ziel-gruppen.
US20050164218A1 (en) * 2003-05-30 2005-07-28 David Agus Gene expression markers for response to EGFR inhibitor drugs
SI2784084T2 (sl) 2003-07-08 2024-02-29 Novartis Pharma Ag Antagonistična protitelesa proti IL-17 A/F heterolognim polipeptidom
US7067274B2 (en) 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
SI2161283T1 (sl) 2003-11-17 2014-10-30 Genentech, Inc. Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
US7348416B2 (en) * 2003-11-21 2008-03-25 Applera Corporation Selective capture and enrichment of proteins expressed on the cell surface
CA2558615C (en) 2004-03-23 2013-10-29 Genentech, Inc. Azabicyclo-octane inhibitors of iap
CN101035802A (zh) 2004-07-02 2007-09-12 健泰科生物技术公司 Iap抑制剂
EA019420B1 (ru) 2004-12-20 2014-03-31 Дженентех, Инк. Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
CA2597325A1 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
WO2006132788A2 (en) 2005-06-06 2006-12-14 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
ZA200800970B (en) 2005-08-15 2009-10-28 Genentech Inc Gene disruptions, compositions and methods relating thereto
ZA200804162B (en) 2005-11-21 2009-12-30 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
AU2006342792A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
EP1982349B1 (de) * 2006-02-07 2018-07-25 DH Technologies Development Pte. Ltd. Unterdrückung von chemischem rauschen für die massenspektrometrie
EP2050335A1 (de) 2006-02-17 2009-04-22 Genentech, Inc. Genunterbrechungen, dazugehörige Zusammensetzungen und Verfahren in Zusammenhang damit
CA2651755A1 (en) 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
EP2057465A4 (de) 2006-08-09 2010-04-21 Homestead Clinical Corp Organspezifische proteine und anwendungsverfahren dafür
US7879799B2 (en) * 2006-08-10 2011-02-01 Institute For Systems Biology Methods for characterizing glycoproteins and generating antibodies for same
US8623606B2 (en) * 2006-08-22 2014-01-07 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Screening method for GPCR ligands
EP2386655B1 (de) 2006-09-12 2014-11-19 Genentech, Inc. Verfahren und Zusammensetzungen zur Diagnose und Behandlung von Lungenkrebs mithilfe des PDGFRA-, KIT- oder KDG-Gens als genetischem Marker
PT2526933E (pt) 2006-09-22 2015-06-23 Pharmacyclics Inc Inibidores da tirosina-quinase de bruton
AU2007337104A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of IAP
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
IL295053A (en) * 2007-03-28 2022-09-01 Pharmacyclics Llc Broton tyrosine kinase inhibitors
AR066348A1 (es) 2007-04-30 2009-08-12 Genentech Inc Inhibidores de las iap
AU2008307145B2 (en) 2007-10-04 2014-07-10 Bionomics Limited Markers of endothelial cells and uses thereof
EP4310194A2 (de) * 2007-10-19 2024-01-24 The Trustees of Columbia University in the City of New York Entwurf und synthese von spaltbaren fluoreszierenden nukleotiden als reversible terminatoren zur dna-sequenzierung durch synthese
WO2009062102A2 (en) 2007-11-07 2009-05-14 Genentech, Inc. Compositions and methods for treatment of microbial disorders
US10107798B2 (en) 2008-03-25 2018-10-23 Sunesis Pharmaceuticals, Inc. Methods of chemotype evolution
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
NZ590550A (en) 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2010028236A1 (en) * 2008-09-05 2010-03-11 Avila Therapeutics, Inc. Algorithm for designing irreversible inhibitors
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
KR20120093220A (ko) * 2009-09-16 2012-08-22 아빌라 테라퓨틱스, 인크. 단백질 키나아제 컨쥬게이트 및 인히비터
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
MX2012006072A (es) 2009-11-30 2012-07-23 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
EP2536748B1 (de) 2010-02-18 2014-08-20 Genentech, Inc. Neuregulin-antagonisten und ihre verwendung zur behandlung von krebs
AU2011221226A1 (en) 2010-02-23 2012-08-16 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2560686A2 (de) 2010-04-21 2013-02-27 Novo Nordisk A/S Selektive modifizierung von proteinen
CN107090045A (zh) 2010-05-03 2017-08-25 霍夫曼-拉罗奇有限公司 用于肿瘤诊断和治疗的组合物和方法
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
WO2012071436A1 (en) 2010-11-24 2012-05-31 Genentech, Inc. Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
WO2012129347A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
WO2012142526A1 (en) 2011-04-14 2012-10-18 Modiano Jaime Use of tumor fas expression to determine response to anti-cancer therapy
WO2012162429A2 (en) 2011-05-23 2012-11-29 The Trustees Of Columbia University In The City Of New York Dna sequencing by synthesis using raman and infrared spectroscopy detection
WO2013010136A2 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN103930781A (zh) 2011-09-15 2014-07-16 霍夫曼-拉罗奇有限公司 促进分化的方法
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
RU2014133547A (ru) 2012-01-18 2016-03-10 Дженентек, Инк. Способы применения модуляторов fgf19
WO2013162654A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of proteins
JP6545959B2 (ja) 2012-02-11 2019-07-17 ジェネンテック， インコーポレイテッド Ｒスポンジン転位およびその使用方法
CN104254541A (zh) 2012-03-16 2014-12-31 弗·哈夫曼-拉罗切有限公司 改造的构象稳定蛋白质
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
RU2014141018A (ru) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг Способы лечения меланомы ингибиторами рак1
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
CA3015208C (en) 2012-06-04 2024-01-02 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
BR112015011171A2 (pt) 2012-11-15 2017-07-11 Pharmacyclics Inc compostos de pirrolopirimidina como inibidores da quinase
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
CN105246511A (zh) 2013-03-06 2016-01-13 豪夫迈·罗氏有限公司 治疗和预防癌症药物抗性的方法
EP2968565A2 (de) 2013-03-14 2016-01-20 Genentech, Inc. Verfahren zur behandlung von krebs und prävention einer antikrebsmittelresistenz
WO2014144883A1 (en) 2013-03-15 2014-09-18 The Trustees Of Columbia University In The City Of New York Raman cluster tagged molecules for biological imaging
CA2905798C (en) 2013-03-15 2023-01-24 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
JP2016520528A (ja) 2013-03-15 2016-07-14 ジェネンテック， インコーポレイテッド 癌の治療及び抗癌剤耐性の防止方法
TR201809571T4 (tr) 2013-03-15 2018-07-23 Hoffmann La Roche Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
BR112015022448B1 (pt) 2013-03-15 2020-12-08 Illumina Cambridge Limited molécula de nucleotídeo ou nucleosídeo modificado, métodos para preparar o crescimento de polinucleotídeo complementar a polinucleotídeo alvo de fita simples em reação de sequenciação e para determinar a sequência de polinucleotídeo alvo de fita simples e kit
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
ES2709509T3 (es) 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
CA2925124A1 (en) 2013-09-30 2015-04-02 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
JP6649895B2 (ja) 2014-04-18 2020-02-19 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
MX2016014504A (es) 2014-05-05 2017-05-23 Regeneron Pharma Animales c5 y c3 humanizados.
JP2017524371A (ja) 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
EP2980126A1 (de) 2014-07-28 2016-02-03 Wacker Chemie AG Verfahren zur Herstellung einer Aminosiloxan Polymer Nanoemulsion
EP2980125B1 (de) 2014-07-28 2017-06-14 Wacker Chemie AG Verfahren zur Herstellung einer Aminosiloxan Polymer Nanoemulsion
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
US11219670B2 (en) 2014-09-05 2022-01-11 The Johns Hopkins University Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
EP3237906B8 (de) 2014-12-23 2020-10-28 Bluelight Therapeutics, Inc. Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion
KR20170122220A (ko) 2015-03-03 2017-11-03 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나제 저해제의 약제학적 제제
EP3273974A4 (de) 2015-03-26 2018-11-07 Women and Infants Hospital of Rhode Island Inc. Therapie für maligne erkrankungen
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
WO2016205681A1 (en) 2015-06-19 2016-12-22 University Of Rochester Septin proteins as novel biomarkers for detection and treatment of müllerian cancers
CA2994413A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma, Inc. Methods for treating myeloproliferative disorders
CN108697793B (zh) 2015-11-23 2023-08-01 阿塞勒隆制药公司 治疗眼睛疾病的方法
US10898483B2 (en) 2015-12-23 2021-01-26 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
WO2017201199A1 (en) 2016-05-17 2017-11-23 Duke University Compositions and methods for the treatment of prader-willi syndrome
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018013936A1 (en) 2016-07-15 2018-01-18 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension
BR112019001615A2 (pt) 2016-07-27 2019-04-30 Acceleron Pharma Inc. métodos e composições para tratar mielofibrose
GB201614152D0 (en) 2016-08-18 2016-10-05 Imp Innovations Ltd Assay
CA3038331A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
SG11201907606XA (en) 2017-02-27 2019-09-27 Regeneron Pharma Humanized model of kidney and liver disorders
JP2020514384A (ja) 2017-03-24 2020-05-21 ジェネンテック， インコーポレイテッド 自己免疫及び炎症性疾患を治療する方法
MX2019012419A (es) 2017-04-21 2019-12-05 Genentech Inc Uso de antagonistas de klk5 para el tratamiento de una enfermedad.
EP3641752A4 (de) 2017-06-22 2021-03-17 Moonshot Pharma LLC Verfahren zur behandlung von krebs mit zusammensetzungen mit amlexanox und immunmodulatoren
US20190211098A1 (en) 2017-12-22 2019-07-11 Genentech, Inc. Use of pilra binding agents for treatment of a disease
US11293061B2 (en) * 2018-12-26 2022-04-05 Illumina Cambridge Limited Sequencing methods using nucleotides with 3′ AOM blocking group
MX2021011609A (es) 2019-03-29 2022-01-24 Genentech Inc Moduladores de interacciones de proteinas de superficie celular y metodos y composiciones relacionados con estos.
WO2021142022A2 (en) 2020-01-06 2021-07-15 Quanta Therapeutics, Inc. Compositions and methods for identification of modulators of ras protein complexes
BR112022026056A2 (pt) 2020-06-22 2023-03-07 Illumina Cambridge Ltd Nucleosídeos e nucleotídeos com grupo bloqueador 3? acetal
WO2022109441A1 (en) 2020-11-23 2022-05-27 Genentech, Inc. Methods for modulating host cell surface interactions with sars-cov-2
EP4251191A1 (de) 2020-11-27 2023-10-04 Genentech, Inc. Verfahren zur modulation der interaktionen der oberfläche von wirtszellen mit dem humanen cytomegalovirus
KR20230116843A (ko) 2020-12-01 2023-08-04 제넨테크, 인크. 세포 표면 단백질을 제시하는 생물학적 소포 및 이와관련된 방법
JP2024512253A (ja) 2021-02-22 2024-03-19 ジェネンテック， インコーポレイテッド 宿主細胞の表面とヘルペスウイルスとの相互作用を調節するための方法
WO2022251461A1 (en) 2021-05-26 2022-12-01 Genentech, Inc. Methods for modulating host cell surface interactions with human cytomegalovirus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196351A (en) 1987-09-30 1993-03-23 Beckman Instruments, Inc. Bidentate conjugate and method of use thereof
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5191066A (en) * 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
US5783384A (en) 1992-01-13 1998-07-21 President And Fellows Of Harvard College Selection of binding-molecules
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
US5571681A (en) * 1994-03-10 1996-11-05 The Scripps Research Institute Chemical event selection by suicide substrate conjugates
ATE307899T1 (de) 1994-11-01 2005-11-15 Ariad Gene Therapeutics Inc Neue methode zum auffindenund bewerten biologisch aktiver moleküle
US5958702A (en) 1995-02-06 1999-09-28 Benner; Steven Albert Receptor-assisted combinatorial chemistry
AU2341397A (en) 1996-03-21 1997-10-10 Princeton University Carbohydrate-based ligand library, assay and method
US5866341A (en) 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
SE9603323D0 (sv) 1996-05-14 1996-09-12 Ahlberg Catalytic method and structure
WO1998011436A1 (en) * 1996-09-13 1998-03-19 Whitehead Institute For Biomedical Research Non-specific affinity enhancement to identify combinatorial library members
AU4351897A (en) 1996-09-16 1998-04-02 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
US5958703A (en) 1996-12-03 1999-09-28 Glaxo Group Limited Use of modified tethers in screening compound libraries
US6428956B1 (en) * 1998-03-02 2002-08-06 Isis Pharmaceuticals, Inc. Mass spectrometric methods for biomolecular screening
US7214487B2 (en) * 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
US6919178B2 (en) * 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
US6998233B2 (en) * 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
MXPA04004814A (es) * 2001-11-21 2004-08-11 Sunesis Pharmaceuticals Inc Metodos para descubrir ligandos.

Also Published As

Publication number Publication date
US20100022399A1 (en) 2010-01-28
US20070026451A1 (en) 2007-02-01
DE69942451D1 (de) 2010-07-15
JP2002519668A (ja) 2002-07-02
US20020022233A1 (en) 2002-02-21
US6811966B2 (en) 2004-11-02
IL140287A (en) 2005-08-31
AU4829999A (en) 2000-01-17
EP1090295B1 (de) 2010-06-02
US20140179542A1 (en) 2014-06-26
WO2000000823A1 (en) 2000-01-06
IL140287A0 (en) 2002-02-10
US20020081621A1 (en) 2002-06-27
CA2336183A1 (en) 2000-01-06
EP1090295A1 (de) 2001-04-11
US6335155B1 (en) 2002-01-01
IL166892A (en) 2009-09-22
US20030104471A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
ATE470150T1 (de) Methode zum schnellen identifizieren von kleinen organischen liganden
ATE337058T1 (de) Kolonne und mit dieser durchgeführtes chromatographisches verfahren
DE60029092D1 (de) Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen
ATE397092T1 (de) Methode zur direkten sequenzierung von nukleinsäuren
NO962991D0 (no) Zink-finger-proteinderivater og fremgangsmåter
ES2182297T3 (es) Deteccion y modulacion de lo inhibidores de las proteinas de la apoptosis (iaps) y de los polipeptidos anti-apoptoticos afines (naip) para la diagnosis y tratamiento de enfermedades proliferativas.
DE69739105D1 (de) Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
DE60033555D1 (de) Verfahren und zusammestellungen zum nachweis und behandlung von brustkrebs, beruhend auf brustkrebs-assoziierten polypeptiden
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
DE69835143D1 (de) Selektion von proteinen mittels rns-protein fusionen
ATE454469T1 (de) Für den nachweis von nukleinsäuren kompetente biologische rohderivate
ATE393237T1 (de) Mittel und verfahren zur in-vitro-bestimmung von camp
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
WO2003002724A3 (en) Proteins, druggable regions of proteins and target analysis for chemistry of therapeutics
ES2191316T3 (es) Procedimiento de deteccion de un material biologico diana, fase de captura, fase de deteccion y reactivo que las contiene.
DE69924147D1 (de) Floureszenzintensitäts-test für eine protein- oder peptidbindung an nukleinsäuren
NO20006153L (no) Poly(ADP-ribose)polymerase gen
ATE357516T1 (de) Modulation molekularer wechselwirkungspositionen in rns und anderen biomolekülen
KR20060021772A (ko) 인산화 단백질 분석용 겔-내 표지화 및 겔-내 단리 방법및 이를 이용한 단백질의 인산화 위치 동정 방법
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect
US20100144044A1 (en) Identification of phosphorylation sites in polypeptides by employment of uranyl photocleavage
SE0201392D0 (sv) Fusion polypeptide, use thereof and methods employing it
ATE331218T1 (de) Verwendung von blauen kupferproteinen
DE59813830D1 (de) Nukleinsäuremolekülsatz für salmonella-nachweis, nukleinsäuren, kit und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties